An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma
文献类型：期刊论文
| 作者 | Li, Meng1,2; Zhang, Lixing2; Ge, Chao2; Chen, Lijuan1,2; Fang, Tao2; Li, Hong2; Tian, Hua2; Liu JX(柳军玺)3 ; Chen, Taoyang4; Jiang, Guoping5
|
| 刊名 | Oncotarget
 |
| 出版日期 | 2015 |
| 卷号 | 6期号:28页码:25149-25160 |
| 关键词 | isocorydine IGF2BP3 cancer stem cell CD133 hepatocellular carcinoma |
| ISSN号 | 1949-2553 |
| 通讯作者 | Li, Jinjun |
| 英文摘要 | In our previous studies, we reported that CD133+ cancer stem cells (CSCs) were chemoresistant in hepatocellular carcinoma (HCC) and that isocorydine treatment decreased the percentage of CD133+ CSCs. Here, we found that a derivative of isocorydine (d-ICD) inhibited HCC cell growth, particularly among the CD133+ subpopulation, and rendered HCC cells more sensitive to sorafenib treatment. d-ICD inhibited IGF2BP3 expression in a time-dependent manner, and IGF2BP3 expression negatively correlated with d-ICD-induced growth suppression. IGF2BP3 overexpression enriched the CD133+ CSC subpopulation in HCC, enhanced tumor sphere formation and suppressed the cytotoxic effects of sorafenib and doxorubicin. The expression of drug resistance-related genes, including ABCB1 and ABCG2, and the CSC marker CD133 expression was increased after IGF2BP3 overexpression. The significance of these observations was underscored by our findings that high IGF2BP3 expression predicted poor survival in a cohort of 236 patients with HCC and positively correlated with ABCG2 and CD133 expression in vivo. These results suggested that the d-ICD may inhibit HCC cells growth by IGF2BP3 decrease and that IGF2BP3 may serve as a therapeutic target for HCC. |
| 学科主题 | 分析化学与药物化学 |
| 收录类别 | SCI |
| 资助信息 | the National Key Program for Basic Research of China (973) (2015CB553905);National Natural Science Foundation of China (81272438;81472726;81301859);Key Discipline and specialty Foundation of Shanghai Municipal Commission of Health and Family Planning, the National Key Sci-Tech Special Project of China (2013ZX10002-011);the SKLORG Research Foundation (91-12-04;91-13-02;91-14-09) |
| 语种 | 英语 |
| WOS记录号 | WOS:000363160100050 |
| 源URL | [http://210.77.64.217/handle/362003/19057]  |
| 专题 | 兰州化学物理研究所_中科院西北特色植物资源化学重点实验室/甘肃省天然药物重点实验室 |
| 作者单位 | 1.School of Basic Medical Science, Shanghai Medical College, Fudan University, Shanghai, China 2.State Key Laboratrory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China 3.Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory Fornatural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, China 4.Qi Dong Liver Cancer Institute, Qi Dong People's Hospital, Qi Dong, Jiangsu Province, China 5.Department of General Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China 6.Cancer Institute of Guangxi, Guangxi Medical University, Nanning, China |
| 推荐引用方式 GB/T 7714 | Li, Meng,Zhang, Lixing,Ge, Chao,et al. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma[J]. Oncotarget,2015,6(28):25149-25160. |
| APA | Li, Meng.,Zhang, Lixing.,Ge, Chao.,Chen, Lijuan.,Fang, Tao.,...&Li, Jinjun.(2015).An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.Oncotarget,6(28),25149-25160. |
| MLA | Li, Meng,et al."An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma".Oncotarget 6.28(2015):25149-25160. |
入库方式： OAI收割
来源：兰州化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。